https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211548
Jan 17, 2024 - Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
zc:-6600895409325080549
0
https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923
Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
zc:3749578308170351338
0
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
zc:5632938074738624243
0
https://www.zacks.com/stock/news/2209670/regeneron-regn-is-up-3-97-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2209670
Jan 12, 2024 - Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
zc:7332615155013535930
0
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
zc:6787123533563202073
0
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
zc:-2407892645345568394
0
https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205808
Jan 04, 2024 - Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
zc:743460894245056112
0
https://www.zacks.com/stock/news/2205668/are-medical-stocks-lagging-aclaris-therapeutics-acrs-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2205668
Jan 04, 2024 - Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
zc:8589283993829156293
0
https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196
Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zc:-4643956653710555069
0
https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2204746
Jan 03, 2024 - SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
zc:3846854905298310363
0